Pages that link to "Q35605724"

The following pages link to Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants (Q35605724):

Displaying 42 items.

• Contributions of human enzymes in carcinogen metabolism (Q30520640) (← links)
• Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP-glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites (Q33714571) (← links)
• UDP-glucuronosyltransferase 1A10: activity against the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, and a potential role for a novel UGT1A10 promoter deletion polymorphism in cancer susceptibility (Q33714575) (← links)
• High-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening (Q34044936) (← links)
• A potential role for human UDP-glucuronosyltransferase 1A4 promoter single nucleotide polymorphisms in the pharmacogenomics of tamoxifen and its derivatives (Q34125047) (← links)
• SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer? (Q34307873) (← links)
• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors (Q34774040) (← links)
• Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy (Q35008045) (← links)
• Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients (Q35691825) (← links)
• First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics (Q36132293) (← links)
• Interindividual differences in phytochemical metabolism and disposition (Q36148997) (← links)
• Identification and functional characterization of a novel UDP-glucuronosyltransferase 2A1 splice variant: potential importance in tobacco-related cancer susceptibility (Q36406279) (← links)
• Phytochemical regulation of UDP-glucuronosyltransferases: implications for cancer prevention. (Q37000698) (← links)
• Differences in metabolite-mediated toxicity of tamoxifen in rodents versus humans elucidated with DNA/microsome electro-optical arrays and nanoreactors (Q37133759) (← links)
• Interindividual differences in response to plant-based diets: implications for cancer risk (Q37179160) (← links)
• Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites (Q37195375) (← links)
• Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen (Q37221922) (← links)
• Glucuronidation of tobacco-specific nitrosamines by UGT2B10 (Q37271209) (← links)
• Do single nucleotide polymorphisms in xenobiotic metabolizing genes determine breast cancer susceptibility and treatment outcomes? (Q37271799) (← links)
• UGT2B gene expression analysis in multiple tobacco carcinogen-targeted tissues (Q37663398) (← links)
• Bioanalytical methods for determination of tamoxifen and its phase I metabolites: A review (Q37811317) (← links)
• Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters (Q37951210) (← links)
• Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid (Q38030052) (← links)
• Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer (Q38103593) (← links)
• Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies (Q38105253) (← links)
• Transcriptional regulation of human UDP-glucuronosyltransferase genes. (Q38261875) (← links)
• Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms. (Q39352329) (← links)
• Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants (Q39507883) (← links)
• UDP-glucuronosyltransferase 1A4 (UGT1A4) polymorphisms in a Jordanian population. (Q39647877) (← links)
• Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype (Q39868674) (← links)
• Stereospecific Metabolism of the Tobacco-Specific Nitrosamine, NNAL. (Q40448416) (← links)
• Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients (Q40789462) (← links)
• A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. (Q43248398) (← links)
• Evaluation of UDP-glucuronosyltransferase 2B17 (UGT2B17) and dihydrofolate reductase (DHFR) genes deletion and the expression level of NGX6 mRNA in breast cancer (Q45153204) (← links)
• The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes (Q48334328) (← links)
• Pharmacokinetics and Safety of Bazedoxifene in Hepatically Impaired and Healthy Postmenopausal Women (Q50005305) (← links)
• Screening of multiple hormonal activities in surface water and sediment from the Pearl River system, South China, using effect-directed in vitro bioassays. (Q52613905) (← links)
• Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma (Q57072034) (← links)
• UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems (Q84411380) (← links)
• Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine (Q86230067) (← links)
• Correlation of the UGT1A4 gene polymorphism with serum concentration and therapeutic efficacy of lamotrigine in Han Chinese of Northern China (Q87859995) (← links)
• Role of l- and d-Menthol in the Glucuronidation and Detoxification of the Major Lung Carcinogen, NNAL (Q90439934) (← links)